Publicaciones

Tabla de contenidos

PART 1. Comorbidity and Brain Disease: Neuronal Substrates

1. Comorbidity Implications in Brain Disease: Neuronal Substrates of Symptom Profiles. Tomás Palomo, Richard J. Beninger, Richard M. Kostrzewa and Trevor Archer
2. The Anatomy of co-Morbid Neuropsychiatric DisordersBased on Cortico-Limbic Synaptic Interactions. Susan Totterdell
3. Disruption of Cortical-Limbic Interaction as a Substrate for Comorbidity. Anthony A. Grace
4. Behavioural Sensitization in Addiction, Schizophrenia, Parkinson´s Disease and Dyskinesia. Werner J. Schmidt and Richard J. Beninger
5. Cognitive Impairment and fMRI in Major Depression. Klaus Ebmeier, Emma Rose and Douglas Steele
6. MAPK and CaMKII-mediated Events During MemoryFormation. Martín Cammarota, Lia R. Bevilaqua, Janine I. Rossato,Carolina Zinn, Jorge H. Medina and Iván Izquierdo
7. The Connection Between the Hippocampal and the Striatal Memory Systems of the Brain: a Review of Recent Findings. Iván Izquierdo, Lia R.M. Bevilaqua, Janine I. Rossato, Juliana S. Bonini, Weber C. Da Silva, Jorge H. Medina and Martín Cammarota
8. Subchronic Administration of Haloperidol Influences the Functional Deficits of Postnatal Iron Administration in Mice. Anders Fredriksson and Trevor Archer
9. Obsessive-Compulsive Disorder as a Disturbance of Security Motivation: Constraints on Comorbidity. Henry Szechtman and Erik Z. Woody
10. Schizophrenia as an Inflammation-Mediated Dysbalance of Glutamatergic Neurotransmission Norbert Müller and Markus Schwarz
11. Inflammation and Depression: Is There a Causal Connection with Dementia? Brian E.Leonard and Ayemu Myint
    

PART 2. Comorbidity and Brain Disease: Symptom Profiles

12. Comorbidity of Substance Abuse with Other Psychiatric Disorders. Tomás Palomo, Trevor Archer, Richard M. Kostrzewa and Richard J.Beninger
13. Animal Models and Treatments for Addiction and Depression Co-morbidity. Neil E. Paterson and Athina Markou
14. The Vulnerability to Alcohol and Substance Abuse in Individuals Diagnosed with Schizophrenia. John H. Krystal, D. Cyril D'souza, Jürgen Gallinat, Naomi Driesen, Anissa Abi-Dargham, Ismene Petrakis, Andreas Heinz and Godfrey Pearlson
15. Neuroplasticity in Postsynaptic Density Proteins in an Animal Model of Addiction and Schizophrenia Comorbidity. Shigenobu Toda and Peter W. Kalivas
16. Are Drugs of Abuse Reinforcing in Patients with Schizophrenia Because They Ameliorate a State of NMDA Deficiency? Bita Moghaddam
17. Importance of Clinical Diagnoses for Comorbidity Studies in Substance Use Disorders. Marta Torrens, Rocío Martin-Santos and Sharon Samet
18. Substance Use Disorders and Schizophrenia: a Question of Shared Glutamatergic Mechanisms. Joseph T. Coyle
    

PART 3. Comorbidity and Brain Disease: Genetic Variation

19. Genetic Variation and Shared Biological Susceptibility Underlying Comorbidity in Neuropsychiatry. Tomas Palomo, Richard M. Kostrzewa, Rick J. Beninger And Trevor Archer
20. From Dopaminergic Genes to Psychiatric Disorders. Janet Hoenicka, María Aragüés, Guillermo Ponce, Roberto Rodríguez-Jiménez, Miguel A. Jiménezarriero and Tomás Palomo
21. Are Some Genetic Risk Factors Common to Schizophrenia, Bipolar Disorder and Depression? Evidence from DISC1, GRIK4 and NRG1. Douglas H.R. Blackwood, Ben J. Pickard, Pippaa. Thomson, Kathryn L. Evans, David J. Porteous and Walter J. Muir
22. Association in Alcoholic Patients Between Psychopathic Traits and the Additive Effect of Allelic Forms of the CNR1 and FAAH Endocannabinoid Genes, and the 3´ Region of the DRD2 Gene. Janet Hoenicka, Guillermo Ponce, Miguel A. Jiménezarriero, Israel Ampuero, Roberto Rodríguez-Jiménez, Gabriel Rubio, Maria Aragüés, Jose A. Ramos and Tomás Palomo
    

PART 4. Comorbidity and Brain Disease: Treatment Strategies

23. Treatment Consideration and Manifest Complexity in Comorbid Neuropsychiatric Disorders. Tomas Palomo, Richard M. Kostrzewa, Richard J. Beninger and Trevor Archer
24. Common Efficacy of Psychotropic Drugs in Restoring Stressinduced Impairment of Prefrontal Plasticity. Nathalie Dupin, François Mailliet, Cyril Rocher, Karima Kessal, Michael Spedding and Therese M. Jay
25. Dopaminergic Dysbalance in Distinct Basal Ganglia Neurocircuits: Implications for the Pathophysiology of Parkinson´s Disease, Schizophrenia and Attention Deficit Hyperactivity Disorder. C. Mehler-Wex, P. Riederer and M. Gerlach
26. Implications of co-Morbidity for Etiology and Treatment of Neurodegenerative Diseases with Multifunctional Neuroprotective-Neurorescue Drugs; Ladostigil. Moussa B.H. Youdim, Tamar Amit, Orit Bar-Am, Orly Weinreb and Merav Yogev-Falach
27. Depressive Comorbidity in Patients with Somatic Pathology A. Lobo, P. Saz, G. Marcos, A. Sarasola, M.F. Barcones, A. Bulbena, J. De Pablo, J.M. Farré, E. García-Camba, J. García-Campayo, M. Girón, M. Lozano, T. Palomo, L. Salvador, A. Campayo and Members Of The Repep Workgroup
28. Dopamine and Incentive Learning: a Framework for Considering Antipsychotic Medication Effects. Richard J. Beninger
29. Comorbidity of Schizophrenia and OCD: Clinical Aspects, Neurobiology and Treatment Abraham Weizman, Ronit Weizman, Camil Fuchs, Amos Frisch and Michael Poyurovsky
30. The Family of Sensorimotor Gating Disorders: Comorbidities or Diagnostic Overlaps? Mark A. Geyer
31. Modeling Tardive Dyskinesia: Predictive 5-HT2C Receptor Antagonist Treatment. Richard M. Kostrzewa, Nuo-Yu Huang, John P. Kostrzewa, Przemyslaw Nowak and Ryszard Brus
32. Pharmacotherapy for Schizophrenia and co-Occurring Substance Use Disorders. Alan I. Green
33. Psychological Intervention for Psychosis and Substance Misuse. Christine Barrowclough
34. Atypical Effects of Atypicals in Schizophrenia. Vicente Molina
35. Epilepsy and Affective Disorder: Clincal Manifestations and Pathophysiological Considerations. Thomas G. Bolwig